Heart failure. Neurohormonal treatment

Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archivos de cardiología de México 2007-10, Vol.77 Suppl 4, p.S4-106-10
1. Verfasser: Martínez Reding, Jesús
Format: Artikel
Sprache:spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 106-10
container_issue
container_start_page S4
container_title Archivos de cardiología de México
container_volume 77 Suppl 4
creator Martínez Reding, Jesús
description Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic system. Angiotensin-II blockage is actually the first option in the medical treatment of HF. Since it reduces cardiac and vascular remodelation, synthesis of collagen and improves the endothelial function. Preceding to this option one can find the use of beta adrenergic blochers. Recently it was discovered that atrial myocardium liberates, in response to stretching, several peptides with natriuretic properties, specially one denominated B. Such compound has utility in the treatment of decompensated heart failure exclusively in hospitalized patients.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70143985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70143985</sourcerecordid><originalsourceid>FETCH-LOGICAL-p546-3dbd7c1907a297485387a45913e932805f1e48c8cc3b853dbd706ad07c702573</originalsourceid><addsrcrecordid>eNo1T7tOwzAU9QCiJfALKFO3oOvYju0RVUCRKhhgjxznRgTFcfBj4O8Jop3OcN4XZEs5iEprDhtyHeMXQC10La7IhirNlIRmS3YHNCGVgxmnHPC-fMUc_KcPzs9mKlNAkxzO6YZcDmaKeHvCgrw_PX7sD9Xx7fll_3CsFsGbivVdLy3VIE2tJVdiLTFcaMpQs1qBGChyZZW1rFvJPzU0pgdp5TpNsoLs_lOX4L8zxtS6MVqcJjOjz7GVQDnTq7Mgdydh7hz27RJGZ8JPe_7FfgFiNkaX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70143985</pqid></control><display><type>article</type><title>Heart failure. Neurohormonal treatment</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Martínez Reding, Jesús</creator><creatorcontrib>Martínez Reding, Jesús</creatorcontrib><description>Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic system. Angiotensin-II blockage is actually the first option in the medical treatment of HF. Since it reduces cardiac and vascular remodelation, synthesis of collagen and improves the endothelial function. Preceding to this option one can find the use of beta adrenergic blochers. Recently it was discovered that atrial myocardium liberates, in response to stretching, several peptides with natriuretic properties, specially one denominated B. Such compound has utility in the treatment of decompensated heart failure exclusively in hospitalized patients.</description><identifier>ISSN: 1405-9940</identifier><identifier>PMID: 18938706</identifier><language>spa</language><publisher>Mexico</publisher><subject>Adrenergic beta-Antagonists - therapeutic use ; Angiotensin II - antagonists &amp; inhibitors ; Heart Failure - drug therapy ; Humans ; Natriuretic Peptide, Brain - therapeutic use</subject><ispartof>Archivos de cardiología de México, 2007-10, Vol.77 Suppl 4, p.S4-106-10</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18938706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martínez Reding, Jesús</creatorcontrib><title>Heart failure. Neurohormonal treatment</title><title>Archivos de cardiología de México</title><addtitle>Arch Cardiol Mex</addtitle><description>Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic system. Angiotensin-II blockage is actually the first option in the medical treatment of HF. Since it reduces cardiac and vascular remodelation, synthesis of collagen and improves the endothelial function. Preceding to this option one can find the use of beta adrenergic blochers. Recently it was discovered that atrial myocardium liberates, in response to stretching, several peptides with natriuretic properties, specially one denominated B. Such compound has utility in the treatment of decompensated heart failure exclusively in hospitalized patients.</description><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Angiotensin II - antagonists &amp; inhibitors</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Natriuretic Peptide, Brain - therapeutic use</subject><issn>1405-9940</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1T7tOwzAU9QCiJfALKFO3oOvYju0RVUCRKhhgjxznRgTFcfBj4O8Jop3OcN4XZEs5iEprDhtyHeMXQC10La7IhirNlIRmS3YHNCGVgxmnHPC-fMUc_KcPzs9mKlNAkxzO6YZcDmaKeHvCgrw_PX7sD9Xx7fll_3CsFsGbivVdLy3VIE2tJVdiLTFcaMpQs1qBGChyZZW1rFvJPzU0pgdp5TpNsoLs_lOX4L8zxtS6MVqcJjOjz7GVQDnTq7Mgdydh7hz27RJGZ8JPe_7FfgFiNkaX</recordid><startdate>200710</startdate><enddate>200710</enddate><creator>Martínez Reding, Jesús</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200710</creationdate><title>Heart failure. Neurohormonal treatment</title><author>Martínez Reding, Jesús</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p546-3dbd7c1907a297485387a45913e932805f1e48c8cc3b853dbd706ad07c702573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2007</creationdate><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Angiotensin II - antagonists &amp; inhibitors</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Natriuretic Peptide, Brain - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martínez Reding, Jesús</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Archivos de cardiología de México</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martínez Reding, Jesús</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heart failure. Neurohormonal treatment</atitle><jtitle>Archivos de cardiología de México</jtitle><addtitle>Arch Cardiol Mex</addtitle><date>2007-10</date><risdate>2007</risdate><volume>77 Suppl 4</volume><spage>S4</spage><epage>106-10</epage><pages>S4-106-10</pages><issn>1405-9940</issn><abstract>Two hypothesis on the cause of heart failure (HF) have been postulated, one of hemodynamic character and another one of neurohormonal nature. According to the second one, HF is consequence of the overactivity of endogenous endocrine systems such as the renin-angiotensin aldosterone or the autonomic system. Angiotensin-II blockage is actually the first option in the medical treatment of HF. Since it reduces cardiac and vascular remodelation, synthesis of collagen and improves the endothelial function. Preceding to this option one can find the use of beta adrenergic blochers. Recently it was discovered that atrial myocardium liberates, in response to stretching, several peptides with natriuretic properties, specially one denominated B. Such compound has utility in the treatment of decompensated heart failure exclusively in hospitalized patients.</abstract><cop>Mexico</cop><pmid>18938706</pmid></addata></record>
fulltext fulltext
identifier ISSN: 1405-9940
ispartof Archivos de cardiología de México, 2007-10, Vol.77 Suppl 4, p.S4-106-10
issn 1405-9940
language spa
recordid cdi_proquest_miscellaneous_70143985
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adrenergic beta-Antagonists - therapeutic use
Angiotensin II - antagonists & inhibitors
Heart Failure - drug therapy
Humans
Natriuretic Peptide, Brain - therapeutic use
title Heart failure. Neurohormonal treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A14%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heart%20failure.%20Neurohormonal%20treatment&rft.jtitle=Archivos%20de%20cardiolog%C3%ADa%20de%20M%C3%A9xico&rft.au=Mart%C3%ADnez%20Reding,%20Jes%C3%BAs&rft.date=2007-10&rft.volume=77%20Suppl%204&rft.spage=S4&rft.epage=106-10&rft.pages=S4-106-10&rft.issn=1405-9940&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70143985%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70143985&rft_id=info:pmid/18938706&rfr_iscdi=true